PERSPECTIVE THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- PERSPECTIVE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.05M, a 26.76% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.55M, a 21.69% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.16M, a 10.45% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.40M, a 234.21% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $8.97M, a 66.44% increase from fiscal 2024.
- PERSPECTIVE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $5.39M, a 44.11% increase from fiscal 2023.
- PERSPECTIVE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.74M.
- PERSPECTIVE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.09M, a 181.61% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.05M 10-Q · filed 2026-08-10 | $5.60M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $2.55M 10-Q · filed 2026-08-10 | ||||
| 2025-12-31 | $8.97M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $2.16M 10-Q · filed 2025-11-10 | $4.56M derived: sum of 2 quarters · filed 2026-08-10 | $6.66M derived: sum of 3 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $2.40M 10-Q · filed 2026-08-10 | $4.50M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $2.10M 10-Q · filed 2026-08-10 | ||||
| 2024-12-31 | $5.39M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $1.95M 10-Q · filed 2025-11-10 | $2.67M derived: sum of 2 quarters · filed 2025-11-10 | $3.33M derived: sum of 3 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $719.00K 10-Q · filed 2025-11-10 | $1.38M derived: sum of 2 quarters · filed 2025-11-10 | |||
| 2024-03-31 | $656.00K 10-Q · filed 2025-11-10 | ||||
| 2023-12-31 | $3.74M 10-K/A · filed 2025-03-28 | ||||
| 2023-09-30 | $451.00K 10-Q · filed 2024-11-12 | $1.65M derived: sum of 2 quarters · filed 2024-11-12 | $3.02M derived: sum of 3 quarters · filed 2024-11-12 | $3.23M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.20M 10-Q · filed 2024-11-12 | $2.57M derived: sum of 2 quarters · filed 2024-11-12 | $2.77M derived: sum of 3 quarters · filed 2024-11-12 | $3.24M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-03-31 | $1.37M 10-Q · filed 2024-11-12 | $1.57M derived: sum of 2 quarters · filed 2024-11-12 | $2.04M derived: sum of 3 quarters · filed 2024-11-12 | $2.19M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2022-12-31 | $207.00K derived: 10-K 6 month − 10-Q 3 month · filed 2024-03-28 | $672.00K 10-K · filed 2024-03-28 | $826.00K derived: sum of 3 quarters · filed 2024-03-28 | $983.00K derived: sum of 4 quarters · filed 2024-03-28 | |
| 2022-09-30 | $465.00K 10-Q · filed 2023-11-14 | $619.00K derived: sum of 2 quarters · filed 2023-11-14 | $776.00K derived: sum of 3 quarters · filed 2023-11-14 | $956.00K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $154.00K 10-Q · filed 2023-11-14 | $311.00K derived: sum of 2 quarters · filed 2023-11-14 | $491.00K derived: sum of 3 quarters · filed 2023-11-14 | $1.09M 10-K · filed 2024-03-28 | |
| 2022-03-31 | $157.00K 10-Q · filed 2023-11-14 | $337.00K derived: sum of 2 quarters · filed 2023-11-14 | $933.00K derived: sum of 3 quarters · filed 2023-11-14 | ||
| 2021-12-31 | $180.00K 10-Q · filed 2022-05-13 | $776.00K derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-09-30 | $596.00K 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | $386.00K 10-KT · filed 2023-05-01 | ||||
| 2021-03-31 | $94.00K 10-Q · filed 2022-05-13 | $175.00K derived: sum of 2 quarters · filed 2022-05-13 | $260.00K derived: sum of 3 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $81.00K 10-Q · filed 2022-05-13 | $166.00K derived: sum of 2 quarters · filed 2022-05-13 | |||
| 2020-09-30 | $85.00K 10-Q · filed 2022-05-13 | ||||
| 2020-06-30 | $495.00K 10-KT · filed 2023-05-01 | ||||
| 2020-03-31 | $91.00K 10-Q · filed 2021-05-14 | $185.00K derived: sum of 2 quarters · filed 2021-05-14 | $276.00K derived: sum of 3 quarters · filed 2021-05-14 | ||
| 2019-12-31 | $94.00K 10-Q · filed 2021-05-14 | $185.00K derived: sum of 2 quarters · filed 2021-05-14 | |||
| 2019-09-30 | $91.00K 10-Q · filed 2021-05-14 | ||||
| 2019-06-30 | $420.00K 10-K · filed 2021-09-27 | ||||
| 2019-03-31 | $79.00K 10-Q · filed 2020-05-13 | $176.00K derived: sum of 2 quarters · filed 2020-05-13 | $269.00K derived: sum of 3 quarters · filed 2020-05-13 | ||
| 2018-12-31 | $97.00K 10-Q · filed 2020-05-13 | $190.00K derived: sum of 2 quarters · filed 2020-05-13 | |||
| 2018-09-30 | $93.00K 10-Q · filed 2020-05-13 | ||||
| 2018-06-30 | $404.00K 10-K · filed 2020-09-25 | ||||
| 2018-03-31 | $77.00K 10-Q · filed 2019-05-10 | $155.00K derived: sum of 2 quarters · filed 2019-05-10 | $245.00K derived: sum of 3 quarters · filed 2019-05-10 | ||
| 2017-12-31 | $78.00K 10-Q · filed 2019-05-10 | $168.00K derived: sum of 2 quarters · filed 2019-05-10 | |||
| 2017-09-30 | $90.00K 10-Q · filed 2019-05-10 | ||||
| 2017-06-30 | $372.00K 10-K · filed 2019-09-27 | ||||
| 2016-06-30 | $291.00K 10-K · filed 2018-09-26 | $290.31K 10-K · filed 2016-09-09 | |||
| 2015-06-30 | $205.00K 10-K · filed 2017-09-28 | $205.26K 10-K · filed 2015-09-14 | |||
| 2014-06-30 | $185.99K 10-K · filed 2016-09-09 | ||||
| 2013-06-30 | $108.35K 10-K · filed 2015-09-14 | ||||
| 2012-06-30 | $173.32K 10-K · filed 2013-09-30 | ||||
| 2011-06-30 | $242.69K 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |